[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100289477":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":13,"centralContacts":17,"locations":22,"responsibleParty":36,"collaborators":10,"id":38,"slug":10,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":10,"eligibilityCriteria":43,"healthyVolunteers":44,"sex":45,"minAge":10,"maxAge":10,"enrollmentInfo":46,"targetDuration":10,"studyType":49,"phases":10,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"MEN1 Patients Who Have Developed Aggressive PNETs-Cases",null,{"label":12,"type":10,"description":10,"interventionNames":10},"MEN1 Patients Who Have Developed Non-Aggressive PNETs-Controls",[14],{"name":15,"affiliation":5,"role":16},"Nancy D. Perrier, MD","PRINCIPAL_INVESTIGATOR",[18],{"name":15,"role":19,"phone":20,"phoneExt":10,"email":21},"CONTACT","713-792-6940","NPerrier@mdanderson.org",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":10},"University of Texas MD Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States",{"type":31,"coordinates":32},"Point",[33,34],-95.36327,29.76328,{"lat":34,"lon":33},{"type":37,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100289477",false,"NCT03048266","Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients","Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients","Inclusion Criteria:\n\n1. The study will include all patients with a confirmed MEN1 diagnosis (clinical, genetic or familial criteria).\n2. No prior history of PNET.\n\nExclusion Criteria:\n\nN\u002FA",true,"ALL",{"count":47,"type":48},629,"ESTIMATED","OBSERVATIONAL","Objectives:\n\nThe aim of the present study is to assess the significance of metabolomics and genetics in diagnosing and survival evaluation for pNET in the periodic follow-up of MEN1 patients.\n\nAim 1: To evaluate the relationship of serum global metabolic profiles with subsequent development of aggressive PNET and evaluate patients survival in a nested case-control study of MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have developed non-aggressive PNETs (controls).\n\nAim 2: Validate the top serum metabolites identified from Aim 1 in MEN1 patients who have developed aggressive PNETs and MEN1 patients who have developed non-aggressive PNETs, using a targeted metabolomics approach.\n\nAim 3: Prospectively identify the potential miRNA biomarkers of serum with miRNA sequencing in MEN1 patients who have developed aggressive PNETs (cases) and MEN1 patients who have developed non-aggressive PNETs (controls).\n\nAim 4: Validate the potential miRNA biomarkers identified from Aim 1 in MEN1 patients who have developed aggressive PNETs and in MEN1 patients who have developed non-aggressive PNETs, using a targeted qRT-PCR approach (in serums), as well as to see the relationship of potential miRNA biomarkers with patients survival.",[52],"Multiple Endocrine Neoplasia",[54,55,56,57,58,59,60,61],"Multiple endocrine neoplasia","MEN1","Aggressive pancreatic neuroendocrine tumors","PNET","Non-aggressive pancreatic neuroendocrine tumors","Metabolomics","Genetics","Biomarkers","2019-05-21",{"date":64,"type":65},"2019-05-23","ACTUAL",{"date":67,"type":65},"2015-11-05",{"date":69,"type":48},"2026-11-01",{"name":5,"class":6},1]